Hypera Past Earnings Performance
Past criteria checks 2/6
Hypera has been growing earnings at an average annual rate of 9.4%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 21.6% per year. Hypera's return on equity is 14.5%, and it has net margins of 21.2%.
Key information
9.4%
Earnings growth rate
9.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 21.6% |
| Return on equity | 14.5% |
| Net Margin | 21.2% |
| Next Earnings Update | 25 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Hypera makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 8,043 | 1,705 | 2,511 | 0 |
| 31 Dec 23 | 7,915 | 1,649 | 2,521 | 0 |
| 30 Sep 23 | 8,189 | 1,772 | 2,531 | 0 |
| 30 Jun 23 | 8,086 | 1,741 | 2,492 | 0 |
| 31 Mar 23 | 7,751 | 1,693 | 2,375 | 0 |
| 31 Dec 22 | 7,546 | 1,705 | 2,299 | 0 |
| 30 Sep 22 | 7,051 | 1,640 | 2,121 | 0 |
| 30 Jun 22 | 6,648 | 1,636 | 2,017 | 0 |
| 31 Mar 22 | 6,260 | 1,660 | 1,955 | 0 |
| 31 Dec 21 | 5,937 | 1,618 | 1,895 | 0 |
| 30 Sep 21 | 5,446 | 1,577 | 1,872 | 0 |
| 30 Jun 21 | 4,902 | 1,462 | 1,756 | 0 |
| 31 Mar 21 | 4,445 | 1,382 | 1,626 | 0 |
| 31 Dec 20 | 4,089 | 1,322 | 1,564 | 0 |
| 30 Sep 20 | 3,883 | 1,243 | 1,538 | 0 |
| 30 Jun 20 | 3,803 | 1,165 | 1,605 | 0 |
| 31 Mar 20 | 3,726 | 1,106 | 1,635 | 0 |
| 31 Dec 19 | 3,295 | 1,189 | 1,611 | 0 |
| 30 Sep 19 | 3,294 | 1,252 | 1,558 | 0 |
| 30 Jun 19 | 3,233 | 1,225 | 1,508 | 0 |
| 31 Mar 19 | 3,180 | 1,164 | 1,469 | 0 |
| 31 Dec 18 | 3,724 | 1,135 | 1,481 | 0 |
| 30 Sep 18 | 3,789 | 1,288 | 1,508 | 0 |
| 30 Jun 18 | 3,716 | 1,251 | 1,477 | 0 |
| 31 Mar 18 | 3,613 | 1,200 | 1,430 | 0 |
| 31 Dec 17 | 3,500 | 1,111 | 1,410 | 0 |
| 30 Sep 17 | 3,291 | 819 | 1,397 | 0 |
| 30 Jun 17 | 3,226 | 795 | 1,380 | 0 |
| 31 Mar 17 | 3,216 | 743 | 1,394 | 0 |
| 31 Dec 16 | 3,228 | 647 | 1,372 | 0 |
| 30 Sep 16 | 3,202 | 557 | 1,360 | 0 |
| 30 Jun 16 | 3,129 | 432 | 1,339 | 0 |
| 31 Mar 16 | 3,046 | 349 | 1,323 | 0 |
| 31 Dec 15 | 2,957 | 345 | 1,307 | 0 |
| 30 Sep 15 | 1,589 | 263 | 774 | 0 |
| 30 Jun 15 | 2,039 | 326 | 944 | 0 |
| 31 Mar 15 | 2,447 | 360 | 1,095 | 0 |
| 31 Dec 14 | 2,768 | 338 | 1,245 | 0 |
| 30 Sep 14 | 4,498 | 400 | 1,913 | 0 |
| 30 Jun 14 | 4,423 | 357 | 1,863 | 0 |
| 31 Mar 14 | 4,359 | 249 | 1,851 | 0 |
| 31 Dec 13 | 4,259 | 259 | 1,804 | 0 |
| 30 Sep 13 | 4,167 | 332 | 1,727 | 0 |
| 30 Jun 13 | 4,047 | 324 | 1,681 | 0 |
Quality Earnings: HYPM.Y has high quality earnings.
Growing Profit Margin: HYPM.Y's current net profit margins (21.2%) are lower than last year (21.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HYPM.Y's earnings have grown by 9.4% per year over the past 5 years.
Accelerating Growth: HYPM.Y's earnings growth over the past year (0.7%) is below its 5-year average (9.4% per year).
Earnings vs Industry: HYPM.Y earnings growth over the past year (0.7%) did not outperform the Pharmaceuticals industry 3.7%.
Return on Equity
High ROE: HYPM.Y's Return on Equity (14.5%) is considered low.